deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT02857426

A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) (CheckMate 647)

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor: Bristol-Myers Squibb

Conditions Lymphoma
Interventions Nivolumab
Updated 23 times since 2017 Last updated: Nov 24, 2021 Started: Oct 21, 2016 Primary completion: Jun 11, 2019 Completion: Nov 24, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Lymphoma, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 23 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Aug 2019 · 6 months · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Nov 2020 · 12 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Jul 2024 · 30 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

23 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Dec 2021 — Jan 2022 [monthly]

    Completed PHASE2

    Status: Active Not RecruitingCompleted

Show 18 earlier versions
  1. Jan 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

  2. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Nov 2019 — Nov 2020 [monthly]

    Active Not Recruiting PHASE2

  4. Aug 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  5. Feb 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  6. Nov 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  7. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  8. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  9. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  10. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  11. Aug 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  12. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

    Status: Active Not RecruitingRecruiting

  13. Jun 2017 — Jul 2017 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  14. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

    Status: Active Not RecruitingRecruiting

  15. Apr 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  16. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE2

  17. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE2

  18. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Ono Pharmaceutical Co. Ltd
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .